Deferasirox for the treatment of iron overlaod associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: A systemetic review and economic evaluation

Health Technology Assessment

Volumn 13, Issue 1, 2009, Pages

  McLeod, C ^a   Fleeman, N ^a   Kirkham, J ^a   Bagust, A ^b   Boland, A ^a   Chu, P ^c   Dickson, R ^a   Dundar, Y ^a   Greenhalgh, J ^a   Modell, B ^d   Olujohungbe, A ^e   Telfer, P ^f   Walley, T ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRITIN; PLACEBO; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; PYRIDONE DERIVATIVE; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; AGE; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTHROPATHY; ASCITES; ASTHENIA; BACKACHE; BETA THALASSEMIA; BILIRUBIN BLOOD LEVEL; BLOOD TRANSFUSION; CHOLECYSTITIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; CREATININE BLOOD LEVEL; CYTOPENIA; DEHYDRATION; DIARRHEA; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DYSPNEA; ECONOMIC EVALUATION; FATIGUE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GLOMERULONEPHRITIS; HEART DISEASE; HEMATOCRIT; HEMOSIDEROSIS; HEPATIC ENCEPHALOPATHY; HEPATITIS; HEPATOBILIARY DISEASE; HUMAN; INFECTION; INFESTATION; INJECTION SITE ABSCESS; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INTERSTITIAL NEPHRITIS; IRON OVERLOAD; JAUNDICE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TUBULE DISORDER; LEUKOPENIA; LIVER FAILURE; LONG TERM CARE; MALAISE; META ANALYSIS; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOMES RESEARCH; PAIN; PATIENT COMPLIANCE; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; REVIEW; RHINOPHARYNGITIS; SICKLE CELL ANEMIA; SIDE EFFECT; SKIN DISEASE; SYSTEMATIC REVIEW; THALASSEMIA MAJOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; UREA BLOOD LEVEL; URINARY DYSFUNCTION; VASCULAR DISEASE; VIRUS INFECTION; VOMITING; BIOMEDICAL TECHNOLOGY ASSESSMENT; CHRONIC DISEASE; COST BENEFIT ANALYSIS; DRUG COMBINATION; DRUG CONTRAINDICATION; ECONOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANEMIA; BENZOATES; BLOOD TRANSFUSION; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DEFEROXAMINE; DRUG THERAPY, COMBINATION; HEMOSIDEROSIS; HUMANS; IRON CHELATING AGENTS; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TREATMENT OUTCOME; TRIAZOLES;

EID: 65449124273     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta13010     Document Type: Review

References (146)

1. Gabutti V, Piga. A. Results of long-term iron-chelating therapy. Acta Haematol 1996;95:26-36.
2. McLaren GD, Muir WA, Kellermeyer RW. iron overload disorders: natural history, pathogenesis, diagnosis, and therapy. Crit Rev Clin Lab Sci 1983;19:205-66.
3. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, et al. Survival in medically treated patients with homozygous beta-thalassemia. N EnglJ Med 1994;331:574-8.
4. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-73.
5. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61.
6. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355:2051-2.
7. VanOrden HE, Hagemann TM. Deferasirox - an oral agent for chronic iron overload. Ann Pharmacother 2006;40:1110-7.
8. Cappellini N, Cohen A, Eleftheriou A, Piga A, Porter J. Iron overload. In Cappellini N, Cohen A, Eleftheriou A, Piga A, Porter J, editors. Guidelines for the clinical management of thalassaemia. Nicosia, Cyprus: Thalassaemia International Federation 2000. p. 21-35.
9. Glader B, editor. Anemia. New York: Raven Press; 1994.
10. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991;325:11-16.
11. Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood 1995;86:776-83.
12. Powars DR, Hiti A, Ramicone E, Johnson C, Chan L. Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic, and genetic factors. Am J Hematol 2002;70:206-15.
13. Manci EA, Culberson DE, Yang Y-M, Gardner TM, Powell R, Haynes, J, Jr, et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol 2003;123:359-65.
14. Amrolia PJ, Almeida A, Halsey C, Roberts IAG, Davies SC. Therapeutic challenges in childhood sickle cell disease. Part 1: current and future treatment options. Br J Haematol 2003;120:725-36.
15. Amrolia PJ, Almeida A, Roberts IAG, Davies SC. Therapeutic challenges in childhood sickle cell disease. Part 2: a problem-orientated approach. Br J Haematol 2003;120:737-43.
16. Vichinsky E, Butensky E, Fung E, Hudes M, Theil E, Ferrell L, et al. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol 2005;80:70-4.
17. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004;103:1934-6.
18. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood 1998;91: 1100]. Blood 1997;89:2079-88.
19. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100:2292-302.
20. Malcovati L, Porta MGD, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-603.
21. Leitch H. Iron chelation therapy improves outcomes in patients with iron overload. American Society of Haematology, 48th Annual Meeting, Orlando, Florida, 2006.
22. DBA-UK. What is Diamond Blackfan anaemia? URL: www.diamondblackfan.org.uk/faq.html. Accessed June 2007.
23. Marsh J, Ball S, Darbyshire P, Gordon-Smith E, Keidan A, Martin A, et al. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol 2003;123:782-801.
24. Office of National Statistics. Population estimates 2005. URL: www.statistics.gov.uk/cci/nugget.asp?id=6. Accessed 20 November 2006.
25. Adams RJ, Brambilla D; Optimizing Primary Stroke Prevention in Sickle Cell Anemia Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005;353:2769-78.
26. Davies S, Cronin E, Gill M, Greengross P, Hickman P, Normand C. Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research. Health Technol Assess 2000; 4(3).
27. Carli PM, Jooste V, Girodon F, Mannone F, Milan C, Maynadie M. Geographical disparities of incidence of myelodysplastic syndromes in a well-defined French population between 1980 and 1997. Leuk Res 2001;25(Suppl 1):A174.
28. Cartwright RA, ed. Incidence and epidemiology of the myelodysplastic syndromes. New York: Churchill Livingstone; 1992.
29. Germing U, Strupp C, Kundgen A, Bowen D, Aul C, Haas R, et al. No increase in age-specific incidence of myelodysplastic syndromes. Haematologica 2004;89:905-10.
30. Radlund A, Thiede T, Hansen S, Carlsson M, Engquist L. Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol 1995;54:153-6.
31. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994;87:743-5.
32. Giralt M, Franco-Garcia E, Giraldo P, Gutierrez M, Angos JA, Perella M. Incidence rates of MDS in a Northern-Spanish area. Leuk Res 1999;23(Suppl 1):S158.
33. Phillips MJ, Cull GM, Ewings M. Establishing the incidence of myelodysplasia syndrome. Br J Haematol 1994;88:896-7.
34. Shimizu H, Matsushita Y, Aoki K, Nomura T, Yoshida Y, Mizoguchi H. Prevalence of the myelodysplastic syndromes in Japan. Int J Hematol 1995;61:17-22.
35. Cartwright RA, Gurney KA, Moorman AV. Sex ratios and the risks of haematological malignancies. Br J Haematol 2002;118:1071-7.
36. Carli PM, Girodon F, Mannone L, Favre B, Mannone C, Caillot D, et al. Update of epidemiological characteristics of myelodysplastic syndromes in a well-defined French population between 1980 and 1995. Leuk Res 1999;23(Suppl 1):23.
37. Maynadie M, Verret C, Moskovtchenko P, Mugneret F, Petrella T, Caillot D, et al. Epidemiological characteristics of myclodysplastic syndrome in a well-defined French population. Br J Cancer 1996; 74:288-90.
38. Bauduer F, Ducout L, Dastugue N, Capdupuy C, Renoux M. Epidemiology of myelodysplastic syndrome in a French general hospital of the Basque country. Leuk Res 1998;22:205-8.
39. Angelucci E, Baronciani D, Lucarelli G, Baldassarri M, Galimberti M, Giardini C, et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol 1995;89:757-61.
40. National Institutes of Health, National Heart Lung and Blood Institute. Management of sickle cell disease, 4th edn. Report No. 02-2117. Bethesda, MD: National Heart Lung and Blood Institute; 2002.
41. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2* magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22:2171-9.
42. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004;127:348-55.
43. Davis BA, Porter JB. Long term outcome of continuous 24 hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassaemia. Blood 2000;95:1229-36.
44. EMEA. Ferriprox EPAR. 1999. URL: www.emea.europa.eu/humandocs/ Humans/EPAR/ferriprox/ferriprox.htm.
45. Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessi C, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005;90:1309-14.
46. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876-84.
47. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary (BNF). No. 53, March 2007. London: BMA and RPS; 2007. URL: www.bnf.org/bnf/.
48. Electronic Medicines Compendium. Desferal - summary of product characteristics. URL: http://emc.medicines.org.uk/. Accessed 28 September 2006.
49. EMEA. Ferriprox: annex I - summary of product characteristics. 2007. URL: www.emea.europa.eu/humandocs/Humans/EPAR/ferriprox/ ferriprox.htm. Accessed 2 February 2007.
50. UK Thalassaemia Society. Standards for the clinical care of children and adults with thalassaemia in the UK. London: UKTS; 2005.
51. Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, et al.; UK. MDS Guidelines Group. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003; 120:187-200.
52. EMEA. Exjade EPAR. 2006. URL: www.emea.europa.eu/humandocs/PDFs/ EPAR/exjade/H670en1.pdf. Accessed 26 October 2006.
53. EMEA. Exjade: annex I - summary of product characteristics. 2007. URL: www.emea.europa.eu/humandocs/Humans/EPAR/exjade/exjade.htm. Accessed 2 March 2007.
54. Novartis. Exjade prescribing information. 2006. URL: www.pharma.us.novartis.com/product/pi/pdf/exjade.pdf.
55. Addis A, Loebstein R, Koren G, Einarson TR. Meta-analytic review of the clinical effectiveness of oral deferiprone (L-1). Eur J Clin Pharmacol 1999;55:1-6.
56. Malaysian Health Technology Assessment Unit. Management of thalassaemia. Kuala Lumpur: Malaysian Health Technology Assessment Unit (MHTAU); 2003.
57. Caro JJ, Huybrechts KF, Green TC. Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review. BMC Blood Disord 2002;2:4.
58. Franchini M, Veneri D. Iron-chelation therapy: an update. Hematol J 2004;5:287-92.
59. Galanello R, Piga A, Alberti D, Rouan MC, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003; 43:565-72.
60. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361:1597-602.
61. Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S. Desferrroxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Cochrane Database Syst Rev 2005;4:CD004450.
62. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107:3455-62.
63. Abetz L, Baladi JF, Jones P, Rofail D. The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual Life Outcomes 2006;4:73.
64. Roberts D, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev 2007;3:CD004839.
65. Moher D, Cook J, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of rrports of meta-analyses of randomised controlled trials: the QUORUM statement. Lancet 1999;354:1896-900.
66. Khan K, Ter Riet G, Glanville J, Sowdon A, Kleijnen J. Undertaking systematic reviews of research on effectiveness. CRDs guidance for carrying out or commissioning reviews. CRD Report No. 4, 2nd edn. York: Centre for Reviews and Dissemination, University of York; 2001.
67. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
68. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
69. Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working. BMJ 1996;313:275-83.
70. Aydinok Y, El-Beshlawy A, von Orelli-Leber C, Czarnecki-Tarabishi C, Manz CY. A randomized controlled trial comparing the combination therapy of deferiprone (DFP) and desferrioxamine (DFO) versus DFP or DFO monotherapy in patients with thalassemia major. American Society of Hematology 48th Annual Meeting, Orlando, Florida, 2006. p. 557.
71. Olivieri NF, Brittenham GM. Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO). Blood 1997; 90(Suppl 1):264a.
72. Shashaty G. Exjade (deferasirox, ICL-670) clinical review (NDA 21-882). 2005. URL: www.fda.gov/ohrms/dockets/ac/05/briefing/ 2005-4177B1_02_b.pdf. Accessed 28 August 2007.
73. Cappellini M, Bejaoui M, Perrotta S, Agaoglu L, Kattamis A, Giardina P, et al. Phase III evaluation of once-daily, oral therapy with ICL670 (Exjade®) versus deferoxamine in patients with β-thalassemia and transfusional haemosiderosis. Blood 2004; 104:984a.
74. Cohen A, Masera G, Zoumbos N, Uysal Z, Boulet D, Watman N, et al. Effect of iron intake on control of body iron in patients with thalassemia major treated. with deferasirox (Exiade®, ICL670). Blood 2005;106:242a.
75. Galanello R. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload. Ann NY Acad Sci 2005;1054:183-5.
76. Kattamis C, Kilinc Y, Fattoum S, Ferster A, Gallisai D, Maggio A, et al. Deferasirox (Eijade®, ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood 2005;106:2692.
77. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-Administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006;91:873-80.
78. Cappellini MD, Galanello R, Piga A, Forni GL, Zanaboni L, Muroni P, et al. Update on the effects of ic1670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. Hematol J 2002(Suppl 1):184.
79. Piga A, Galanello R, Cappellini MD, Forni G, Opitz H, Ford JM, et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood 2002;100:5A-A.
80. Piga A, Galanello R, Cappellini MD, Forni GL, Lupo G, Ford JM, et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood 2003;102:121a.
81. Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, et al. A randornised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007;136:501-8.
82. Vichinsky E, Fischer R, Fung E, Onyekwere O, Porter J, Swerdlow P, et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once-daily oral iron chelator deferasirox (Exjade® ICL670) is well tolerated and reduces iron burden. Blood 2005;106:313.
83. Olivieri NF, Koren G, Hermann C, Bentur Y, Chung D, Klein J, et al. Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded patients. Hematol Rev Comm 1992;6:147-52.
84. Olivieri NF, Templeton DM, Koren G, Chung D, Hermann C, Freedman MH, et al. Evaluation of the oral iron chelator,1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients. Ann NY Acad Sci 1990;612:369-77.
85. Olivieri NF, Koren G, Hermann C, Bentur Y, Chung D, Klein J, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 1990;336:1275-9.
86. Olivieri NF, Brittenham GM, Armstrong SAM, Basran RK, Daneman R, Daneman N, et al. First prospective randomized trial of the iron chelators deferiprone (L1) and deferoxamine. Blood 1995; 86(10Suppl1):249a.
87. Basran RK, Fassos FF, Shaw D, Olivieri NF. Assessment of the relative quality of life in patients receiving subcutaneous deferoxamine and the orally active iron chelating agent L1. Blood 1994;84(Suppl 1):261a.
88. Olivieri NF, Sher GD, MacKinnon JA, Pope I, Entsuah B, Snider MA, et al. The first prospective randomized trial of subcutaneous deferoxamine and the orally active iron chelating agent L1. Blood 1994;84:363a.
89. Olivieri N; the Iron Chelation Research Group. Randomized trial of deferiprone (L1) and deferoxamine (DFO) in thalassemia major. Blood 1996;88(Suppl 1):651a.
90. Olivieri NF, Brittenham GM. Evidence of progression of myocardial iron loading as determined by magnetic resonance imaging (MRI) in thalassemia patients during treatment with deferiprone (L1) and deferoxamine (DFO). Blood 1999;94:35B-B.
91. Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002; 28:196-208.
92. Maggio A, Capra M, Ciaccio C, Magnano C, Rizzo M, Mangiagli A, et al. Evaluation of efficacy of L1 versus desferrioxamine by clinical randomized multicentric study. Blood 1999;94(Suppl 1):34b.
93. Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam W, et al. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin 2006;30:263-74.
94. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial sideresis. Blood 2006;107:3738-44.
95. Gomber S, Saxena R, Madan N. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Ind Pediatr 2004;41:21-7.
96. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher, A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003;121:187-9.
97. Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 2006; 91:1241-3.
98. Porter JB, Tanner MA, Pennell DJ, Eleftheriou P. improved myocardial T2* in transfusion dependent anemias receiving ICL670 (Deferasirox). Blood 2005;106:3600.
99. Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Khan M, et al. A randomized, placebo controlled, double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance. Blood 2005;106:3655.
100. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006;295:1152-60.
101. Aydinok Y, Evans P, Terzi A, Cetiner N, Porter JB. Randomised prospective evaluation of iron balance, chelation efficiency, urine excretion and NTBI progression with deferiprone (DFP) or deferoxamine (DFO) monotherapy or with combined DFP plus DFO. Blood 2005; 106:2698.
102. Aydinok Y, El-Beshlawy A, von Orelli-Leber C, Czarnecki-Tarabishi C, Manz CY. A randomized controlled trial comparing the combination therapy of defeiprone (DFP) and desferrioxamine (DFO) versus DFP or DFO monotharpy in patients with thalassemia major. American Society of Hematalogy 48th Annual Meeting, Orlando, Florida, 2006. PowerPoint Presentation.
103. Maggio A, D'Amico G, Morabito A. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial - reply. Blood Cells Mol Dis 2004;32:141-2.
104. Galanello R, Kattamis A, Piga A, Tricta F. Safety and efficacy of alternate desferrioxamine and deferiprone compared to desferrioxamine alone in the treatment of iron overload in transfusion-dependent thalassemia patients. Blood 2004;104:982a.
105. Bennett W, Ponticelli C, Piga A, Kattamis A, Glimm E, Ford J. Summary of long-term renal safety data in transfused patients with secondary iron overload receiving deferasirox (Exjade®, ICL670). American Society of Hematology 48th Annual Meeting, Orlando, Florida, 2006. p. 3816.
106. Cappellini MD, Giardina P, Porter J, Coates T, Delia Porta MG, Siegel J, et al. Long-term safety and tolerability of the once-daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. American Society of Hematology 48th Annual Meeting, Orlando, Florida, 2006. p. 1768.
107. Piga A, Bejaoui M, Kilinc Y, Perrotta S, Vichinsky E, Arrowsmith-Bensasson C, et al. Long-term treatment with the once-daily oral iron chelator deferasirox (Exjade®, ICL670) is effective and generally well tolerated in pediatric patients. American Society of Hematology 48th Annual Meeting, Orlando, Florida, 2006. p. 1781.
108. Cappellini MD, Vichinsky E, Galanello R, Piga A, Williamson P, Porter JB, et al. Long-term treatment with deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, is effective in patients with transfusion-dependent anemias. American Society of Hematology 49th Annual Meeting, Atlanta, Georgia, 2007.
109. Piga A, Vichinsky E, Forni GL, Kilinc Y, Maseruka H, Kattamis A. Long-term efficacy and safety with deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, in pediatric patients. American Society of Hematology 49th Annual Meeting, Atlanta, Georgia, 2007.
110. Vichinsky E, Coates TD, Thompson AA, Mueller BU, Lagrone D, Heeney MM. Long-term efficacy and safety of deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, in patients with sickle cell disease (SCD). American Society of Hematology 49th Annual Meeting, Atlanta, Georgia, 2007.
111. Kontoghiorghes GJ. Deferasirox: uncertain future following renal failure fatalities, agranulocytosis an other toxicities. Exp Opin Drug Saf 2007;6:235-9.
112. US Food and Drug Administration. New molecular entity (NME) - early safety findings: deferasirox (markeied as Exjade®). FDA Drug Safety Newsletter 2007;1(1):8-9.
113. Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther 2007;29:909-17.
114. Dundar Y, Dodd S, Dickson R, Walley T, Haycox A, Williamson PR. Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies. Health Technol Assess 2006;10(5).
115. Dundar Y, Dodd S, Williamson P, Dickson R, Walley T. Case study of the comparison of data from conference abstracts and full-text articles in health technology assessment of rapidly evolving technologies: does it make a difference? Int J Technol Assess Health Care 2006; 22(3):288-94.
116. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006;107:3733-7.
117. Ceci A, Baiardi P, Catapano M, Felisi M, Cianciulli P, De Sanctis V, et al. Risk factors for death in patients with beta-thalassemia major: results of a case-control study. Haematologica 2006; 91:1420-1.
118. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88:489-96.
119. Berdoukas V, Modell B. transfusion dependent thalassaemia - a new era. Med J Aust 2008;188:68-9.
120. Piga A, Longo F, Consolati A, De Leo A, Carmellino L. Mortality and morbidity in thalassaemia with conventional treatment. Bone Marrow Transplant 1997;19(Suppl 2):11-13.
121. List AF, Baer M, Steensma D, Raza A, Esposito J, Virkus J, et al. Deferasirox (ICL670; Exjade®) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS). American Society of Hematology 49th Annual Meeting, Atlanta, Georgia, 2007.
122. Pbrter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Capellini MD, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2007 Nov 17; published article online. URL: www.blackwell-synergy.com.ezproxy.liv.ac.uk/toc/ejh/0/0. Accessed 30 November 2007.
123. Galanello R, Piga A, Foschini ML, Zappu A, Bordone E, Longo F, et al. Pharmacokinetic evaluation of ICL670, a once-daily oral iron chelator, in pediatric patients with β-thalassemia major. Pediatr Blood Cancer 206;44:550.
124. Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 2004;170:477-80.
125. Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 1994;154:157-63.
126. Delea TE, Thomas SK, Baldi JF, Coates TD. Once-daily oral deferasirox (Exjade®, ICL670) versus infusional deferoxamine as iron chelation therapy in patients with sickle-cell disease receiving frequent transfusions: a cost-effectiveness analysis. Blood 2005; 106:5584.
127. Delea TE, Thomas SK, Baladi JF, Phatak PD. Cost-effectiveness analysis of oral iron chelation therapy with deferasirox (Exjade®, ICL670) versus infusional chelation therapy with deferoxamine in patients with transfusion-dependent myelodysplastic syndrome. Blood 2005; 106:5585.
128. Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD, et al. Cost-effectiveness of once-daily oral chelation therapy with deferasirox (Exjade®, ICL670) versus infusional deferoxamine in transfusion-dependent thalassemic patients. Blood 2005; 106:1341.
129. Delea T, Sofrygin O, Thomas S, Baladi JF, Phatak P, Coates TD, et al. Cost-effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassemia patients. Value Health 2006;9:A143-A.
130. Delea TE, El Ouagari K, Sofrygin O. Cost of current iron chelation infusion therapy and cost-effectiveness of once-daily oral deferasirox in transfusion-dependent thalassemia patients in Canada. American Society of Hematology 48th Annual Meeting, Orlando, Florida, 2006. p. 3349.
131. Delea T, Sofrygin O, Thomas S, Baladi JF, Phatak P, Coates TD. Cost-effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassemia patients: US healthcare system perspective. Pharmacoeconomics 2007;25:329-42.
132. Delea TE, Sofrygin O, Baladi J-F, Thomas SK, Phatak PD, Coates TD, et al. Sensitivity analysis on the cost-effectiveness of chelation therapy with deferasirox or deferoxamine in transfusion-dependent thalassemia patients based on European costs. European Hematology Association 11th Annual Congress, Amsterdam, 2006.
133. Calebro A, Delea TE, Sofrygin O, Coates TD, Phatak PD, et al. Cost-effectiveness of once-daily oral chelation therapy with deferasirox (Exjade®) versus infusional deferoxamine in transfusion-dependent thalassemic patients: a Brazilian perspective. European Hematology Association 11th Annual Congress, Amsterdam, 2006.
134. Karnon J, Akehurst R, Papo N. Cost utility analysis of deferasirox (Exjade®) versus deferoxamine (Desferal) for patients requiring iron chelation therapy in the United Kingdom. European Hematology Association 11th Annual Congress, Amsterdam, 2006.
135. Karnon J, Akehurst R, Jewitt K, Ossa D. Cost utility analysis of deferasirox (Exjade®) versus deferoxamine (Desferal) for patients requiring iron chelation therapy in the United Kingdom. European Hematology Association 12th Annual Congress, Vienna, 2007.
136. De Abreu Lourenco R, Osborne R, Dalton A, Houltram J, Dowton D, Joshua D, et al. An oral iron chelator and quality of life. American Society of Hematology 47th Annual, Meeting, Atlanta, Georgia, 2005. p. 5553.
137. Osborne R, De Abreu Lourenco R, Dalton A, Houltram J, Dowton D, Joshua D, et al. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health 2007; 10:451-6.
138. Red book update December 2006. Montvale, NJ:Thomson Healthcare, 2005.
139. Arboretti R, Tognoni G, Alberti D. Pharmacosurveillance and quality of care of thalassaemic patients. Eur J Clin Pharmacol 2001; 56:915-22.
140. Kremastinos D, Tsetsos G, Tsiapras D, Karavolias G, Ladis V, Kattamis C. Heart failure in beta-thalassaemia: a five-year follow-up study. Am J Med 2001;111:349-54.
141. Fryback D, Dasbach E, Klein R, Klein B, Dorn N, Peterson K, et al. The Beaver Dam health outcomes study: initial catalog of health state quality factors. Med Decis Making 1993;13:89-102.
142. Alderson P. Absence of evidence is not evidence of absence. BMJ 2004;328:476-7.
143. Mullhaven. Price list. URL: www.mullhaven.co.uk/ webpagepricelist.htm. Accessed June 2007.
144. Desrosiers M-P, Payne KA, Baladi J-F. Estimating the total cost of infused iron chelation therapy. American Society of Hematology 47th Annual Meeting, Atlanta, Georgia 2005. p. 5576.
145. Harlow Healthcare. Health for all children. URL: http://shop.healthforallchildren.co.uk/pro.epl?SHOP=HFAC4&DO= USERPAGE&PAGE=SINGLEPLOTSICKHEIGHT. Accessed October 2007.
146. Malaysian Health Technology Assessment Unit. Management of thalassaemia (structured abstract). 2003. URL: www.mrw.interscience.wiley.com/cochrane/clhta/articies/HTA-20031139/ frame.html.